Oncology Business Management

More than half (54%) of practices are struggling with rising costs of equipment and facilities, staffing costs, and administration expenses.

Results of a study indicate that 44.7% of practicing oncologists show signs of burnout.

Barbara McAneny, MD, hopes she can help fix American healthcare’s shortcomings while also promoting its strengths by running for president of the American Medical Association (AMA).

When it comes to achievements in the war against cancer, there’s much to celebrate, ASCO said in its fourth annual report on the state of cancer care in America, which we discuss in our lead story this month for Oncology Business ManagementTM.

A biologics license application has been submitted for axicabtagene ciloleucel as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Tricia Strusowski, MS, RN, discusses the role of the oncology nurse navigator and how these staffers can help meet outcome and quality standards set by the CMS's OCM.

The outgoing president of the Association of Community Cancer Centers, Jennie Crews, MD, MMM, FACP reflects on her time as president and the achievements the ACCC made.

While at the annual CANCERSCAPE meeting of ACCC, Kavita Patel, MD, MS, comments on uncertainy in the healthcare environment and key policy to be aware of.

The FDA has granted a regular approval to osimertinib as a treatment for patients with metastatic EGFR T790M mutation-positive non–small cell lung cancer following prior treatment with an EGFR TKI, based on progression-free survival findings from the phase III AURA3 trial.

The Republican-led Affordable Care Act repeal and replace effort has the potential to be revived, but majority leaders may not want to risk further political capital in a battle that could go against them, speakers said at this year's Association of Community Cancer Centers' CANCERSCAPE annual conference.

Daniel F. Hayes, MD, and Stephen S. Grubbs, MD, discuss the perception that ASCO has not been truly representative of smaller, independent oncology practices throughout the United States, and how they plan to remedy that.

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

The FDA's Oncologic Drugs Advisory Committee unanimously (11-0) recommended approval of subcutaneous rituximab for the treatment of patients with certain blood cancers.

The Affordable Care Act has improved access to cancer care for millions of Americans, and many new drugs and new indications for existing cancer drugs were approved in 2016, but there are frontiers in improving cancer care that include information barriers, disparities in the availability of rural care, and stressors on physicians and oncology practices, ASCO said in its annual report State of Cancer Care in America: 2017.

Array BioPharma has withdrawn its new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma, based on feedback from the FDA during a preplanned review meeting.

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

Andrew L. Pecora, MD, has been awarded the inaugural Rosemarie J. Sorce Endowed Chair in Innovation at Hackensack Meridian Health.

Healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer, indicating a need for better targeted treatments for this patient class.

The Affordable Care Act has given rise to healthcare upon which many now depend. Those with an ear to the tracks in Washington, DC, believe that something new is definitely on the way.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).

The partners at Cancer Center of Kansas have heard for years about all the radical changes they must make to survive as a business. They have implemented those changes required by law, but they have stood firm against fads.

Andrew L. Pecora, MD, discusses his hopes for healthcare reform if the the Affordable Care Act is repealed.

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Oncologists discuss their experience and best practices with phone triage programs.